Sort
39,280 grants matching “leukemia”
Molecular basis of the requirements for IRF4 and IRF8 in pre-B cell development
$350,063Runqing Lu · University Of Nebraska Medical Center · R01 · FY2009 · AI
Molecular basis of the requirements for IRF4 and IRF8 in pre-B cell development
$350,063Runqing Lu · University Of Nebraska Medical Center · R01 · FY2008 · AI
Genetic control of limb development by Pbx
$350,001Licia Selleri · Weill Medical Coll Of Cornell Univ · R01 · FY2010 · HD
North Shore CCOP
$350,000Vincent P Vinciguerra · Feinstein Institute For Medical Research · U10 · FY2009 · CA
Regulation of stalled fork repair in mammalian cells
$350,000Ralph Scully · Beth Israel Deaconess Medical Center · R01 · FY2021 · GM
Regulation of stalled fork repair in mammalian cells
$350,000Ralph Scully · Beth Israel Deaconess Medical Center · R01 · FY2019 · GM
Regulation of stalled fork repair in mammalian cells
$350,000Ralph Scully · Beth Israel Deaconess Medical Center · R01 · FY2020 · GM
EPIDEMIOLOGY OF T-CELL LEUKEMIA/LYMPHOMA
$350,000University Of The West Indies · N01 · FY2000 · CP
Regulation of stalled fork repair in mammalian cells
$350,000Ralph Scully · Beth Israel Deaconess Medical Center · R01 · FY2022 · GM
Genetic Mechanisms of Anthracycline Cardiotoxicity in Pediatric Cancer Survivors
$349,997Steven Edward Lipshultz · University Of Miami School Of Medicine · R01 · FY2007 · CA
The phosphatase PRL3 as a MYC target and pro-survival oncogene in Acute Lymphoblastic Leukemia
$349,988Jessica S. Blackburn · University Of Kentucky · R37 · FY2020 · CA
The phosphatase PRL3 as a MYC target and pro-survival oncogene in Acute Lymphoblastic Leukemia
$349,988Jessica S. Blackburn · University Of Kentucky · R37 · FY2018 · CA
The phosphatase PRL3 as a MYC target and pro-survival oncogene in Acute Lymphoblastic Leukemia
$349,988Jessica S. Blackburn · University Of Kentucky · R37 · FY2021 · CA
The phosphatase PRL3 as a MYC target and pro-survival oncogene in Acute Lymphoblastic Leukemia
$349,988Jessica S. Blackburn · University Of Kentucky · R37 · FY2022 · CA
Data Compilation Core
$349,942Stephen L George · Univ Of North Carolina Chapel Hill · P01 · FY2010 · CA
Recombinant human lactoferrin to treat oral mucositis
$349,929Agennix, Inc. · R43 · FY2004 · DE
Targeted Oral Anticancer Agents: Patterns of Indicated and Off-Label Use, the Associated Factors, and Economic Implications
$349,924Ya-Chen Tina Shih · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA
Role of C/EBPalpha in MDS and MDS Progression
$349,879Alan D Friedman · Johns Hopkins University · R01 · FY2008 · HL
Project 1: Chimeric antigen receptor T-cell therapy for T cell malignancies
$349,875John F Dipersio · Washington University · P50 · FY2025 · CA
Project 4: Targeting ATR in TP53-mutated MDS/AML
$349,875Daniel C Link · Washington University · P50 · FY2025 · CA
Project 2: Memory-like NK cell therapy for AML relapsed after allogeneic transplant
$349,875Todd A Fehniger · Washington University · P50 · FY2025 · CA
LY-1 B CELLS--DEVELOPMENTAL ORIGINS AND V GENE
$349,795Institute For Cancer Research · R01 · FY2000 · AI
Novel Strategy for BIV Vector Site-Specific Integration
$349,780Sheila Connelly · Advanced Vision Therapies, Inc. · R43 · FY2006 · GM
Validating and targeting USP35 for anticancer drug development
$349,766Changwei Liu · University Of Colorado Denver · U01 · FY2018 · CA
Eicosanoids and Vascular Wall Remodeling
$349,750Gadiparthi N Rao · University Of Tennessee Health Sci Ctr · R01 · FY2012 · HL